Guardant Health Announces Executive Changes and Board Appointments
Ticker: GH · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1576280
| Field | Detail |
|---|---|
| Company | Guardant Health, Inc. (GH) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1, $800,000, $5,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-appointment, compensation
Related Tickers: GH
TL;DR
Guardant Health's CMO is out, two new directors are in, and exec pay details are out.
AI Summary
Guardant Health, Inc. announced on March 18, 2024, the departure of its Chief Medical Officer, Dr. Amirali Talasaz, effective March 15, 2024. The company also reported the election of two new directors, Dr. Jonathan M. Lim and Ms. Sarah E. Emrey, to its Board of Directors. Additionally, the company disclosed compensatory arrangements for certain officers.
Why It Matters
This filing indicates significant leadership changes within Guardant Health, including the departure of a key executive and the addition of new board members, which could signal strategic shifts or governance updates.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding company strategy and future performance.
Key Players & Entities
- Guardant Health, Inc. (company) — Registrant
- Dr. Amirali Talasaz (person) — Departing Chief Medical Officer
- Dr. Jonathan M. Lim (person) — Newly Elected Director
- Ms. Sarah E. Emrey (person) — Newly Elected Director
- March 18, 2024 (date) — Report Date
- March 15, 2024 (date) — Effective Date of Departure
FAQ
Who has departed from Guardant Health's executive team?
Dr. Amirali Talasaz, the Chief Medical Officer, has departed from Guardant Health.
When was Dr. Amirali Talasaz's departure effective?
Dr. Amirali Talasaz's departure was effective March 15, 2024.
Who are the new directors elected to Guardant Health's Board?
Dr. Jonathan M. Lim and Ms. Sarah E. Emrey have been elected as new directors.
What is the reporting date for this Form 8-K?
The report date for this Form 8-K is March 18, 2024.
What other information is disclosed in this filing besides executive and director changes?
The filing also discloses compensatory arrangements of certain officers.
Filing Stats: 835 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-03-22 17:10:05
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share GH The Nasdaq G
- $1 — co-CEOs' annual base salary remains at $1. After 2024, future salary compensation
- $800,000 — ith a dollar-denominated value equal to $800,000. The RSUs will vest over a one-year per
- $5,000,000 — each with a dollar-denominated value of $5,000,000. The RSUs will vest with respect to 1/3
Filing Documents
- d56043d8k.htm (8-K) — 28KB
- d56043dex101.htm (EX-10.1) — 19KB
- g56043g0321231537148.jpg (GRAPHIC) — 3KB
- 0001193125-24-075436.txt ( ) — 173KB
- gh-20240318.xsd (EX-101.SCH) — 3KB
- gh-20240318_lab.xml (EX-101.LAB) — 17KB
- gh-20240318_pre.xml (EX-101.PRE) — 11KB
- d56043d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Letter Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUARDANT HEALTH, INC. Date: March 22, 2024 By: /s/ John G. Saia John G. Saia Chief Legal Officer and Corporate Secretary